Clinical trial shows promising treatment for fragile X, Autism

A new drug compound known as STX 209, or Arbaclofen, is showing promise for treating some of the symptoms of fragile X syndrome and some types of autism. A clinical trial involving patients ages 6 to 39 with fragile X showed some improvement in social withdrawal and other challenging behaviors. "This is the first large-scale study that is based on the molecular understanding of fragile X syndrome and, importantly, suggests that the core symptoms may be amenable to pharmacologic treatment," the study's lead author, Elizabeth Berry-Kravis of Rush University Medical Center, said. Disability Scoop (9/20)  http://www.disabilityscoop.com/2012/09/20/drug-treat-fragile-autism/16484/